Drug Type Antibody drug conjugate (ADC) |
Synonyms CAB-B7-H4 |
Target |
Mechanism B7-H4 modulators(V-set domain-containing T-cell activation inhibitor 1 modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Phase 1 | US | 01 Aug 2022 | |
Breast Cancer | Preclinical | GT | 16 Jul 2024 | |
Colonic Cancer | Preclinical | GT | 16 Jul 2024 | |
Kidney Neoplasms | Preclinical | GT | 16 Jul 2024 | |
Ovarian Cancer | Preclinical | GT | 16 Jul 2024 | |
Prostatic Cancer | Preclinical | GT | 16 Jul 2024 |